<a href="https://laohu8.com/S/TRAW">Traws Pharma</a> Grants Stock Options to Executive Team
Traws Pharma Inc. has approved new stock option grants for its executive officers. On October 12, 2025, the company's Compensation Committee granted options to purchase shares of common stock at an exercise price of $3.01 per share. The grants include 64,839 options to Chief Executive Officer Iain Dukes, 32,406 options each to Chief Financial Officer Charles Parker, Chief Science Officer, Virology C. David Pauza, and Chief Medical Officer Robert Redfield, and 22,435 options to Chief Operating Officer Nikolay Savchuk. The options have a ten-year term and will vest in full on the first anniversary of the grant date, provided the recipients remain with the company. These options were issued under Traws Pharma's Amended and Restated 2021 Incentive Compensation Plan.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-100455), on October 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.